Endocardial catheter ablation versus thoracoscopic ablation in de novo persistent atrial fibrillation patients with enlarged left atrium : A Randomized Controlled Trial

Samsung Medical Center0 个研究点目标入组 194 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•1. 19 years of age or older
•2. Patients with persistent atrial fibrillation who have failed antiarrhythmic treatment or are unable to maintain antiarrhythmic drugs
•3. European Heart Rhythm Association score for AF(EHRA) = 2
•4. A person who is deemed appropriate to treat atrial fibrillation rhythm control through percutaneous catheter resection or thoracoscopic resection (prescribed by the investigator as medical judgment)
•5. Patients with left atrial hypertrophy (LA diameter = 50 mm or LAVI = 45 ml/?)

•1. Patients who have undergone percutaneous catheter resection or thoracoscopic resection for past atrial fibrillation
•2. a patient who has had past chest or heart surgery
•3. If there is an absolute contraindication to anticoagulant therapy
•4. A person whose life expectancy is less than one year due to a non-heart disease or who is expected to be less compliant with treatment (as determined by the investigator by medical judgment)
•5. a patient who refused to participate in the study

发起方